Abstract 1774P
Background
In a recently published manuscript we demonstrated significant decreases in mental distress, anxiety and depression compared to standard of care following a 6m daily comprehensive program developed with patient engagement. Here we conduct secondary analyses examining the effects of this Prostate Cancer-Patient Empowerment Program (PC-PEP) on patient-reported urinary, bowel, sexual, hormonal and physical function among men scheduled for curative prostate cancer (PC) treatment.
Methods
This crossover randomized clinical trial evaluated 128 men aged 50–82 yr scheduled for curative prostate cancer surgery or radiotherapy (± hormone), 66 received the 6-mo PC-PEP intervention and 62 were randomized to standard of care for 6m and received PC-PEP to the end of the year. PC-PEP comprises regular physical strength and PFMT training, daily dietary advice, bio-feedback stress reduction, and social networking. Weekly online compliance surveys, the International Prostate Symptom Score (IPSS), Expanded Prostate Cancer Index Composite (EPIC), and SF-12 at baseline, 6 and 12m were completed. MLM analyses were used to evaluate the results.
Results
Baseline patient characteristics and outcomes between the two groups were comparable, and weekly compliance for PC-PEP was high among both groups (early v. late intervention). At six months, the PC-PEP group had improved IPSS bother score, EPIC Urinary Incontinence, EPIC Irritative/Obstructive score, physical fitness (lower weight and BMI), SF-12 physical, and mental health function when compared to the control group (p=0.004, p=0.001, p=0.008, p=0.001, p=0.002, and p=0.003 respectively). Analyses revealed that providing the intervention early or late was equally beneficial to patients. No other significant results emerged.
Conclusions
PC-PEP significantly improves lower urinary tract symptoms, physical function and overall quality of life among men scheduled for curative PC treatment compared to standard of care. The program is being currently tested in an international phase 4 trial.
Clinical trial identification
NCT03660085.
Editorial acknowledgement
Legal entity responsible for the study
Nova Scotia Health Authority, Canada.
Funding
Research Nova Scotia Establishment Grant (#2215).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14